SU 10603

SKU: orb1699224

Description

SU 10603 is a potent and selective small molecule inhibitor of the enzyme 17α-hydroxylase/CYP17A1, a key target in steroidogenesis research. It is widely used in both in vitro and in vivo studies to investigate androgen and cortisol synthesis pathways relevant to diseases like prostate cancer and Cushing's syndrome.

Research Area

Metabolism Research

Key Properties

• CAS Number: 786-97-0
• MW: 257.72
• Purity: 99.96% (May vary between batches)
• Formula: C₁₅H₁₂ClNO
• SMILES: Clc1ccc2CCC(C(=O)c2c1)c1cccnc1
• Target: Hydroxylase,Cytochromes P450

Bioactivity

• In Vivo:
  Methods: NNC 05-711 (50, 100, 200 μg/10 μL, intrathecal injection, once a day) was used to treat rats with chronic sciatic nerve constriction injury (CCI) and its analgesic effect was observed. Results: NNC 05-711 exerted an effective analgesic effect in the CCI rat model. Compared with the CCI + saline group, the paw withdrawal threshold (WT) and paw withdrawal latency (WL) values ​​increased after 1 day.
  Read more...
• In Vitro:
  Treatment of 661 W cells with SU 10603 (10 μM) prevents the conversion of pregnenolone to dehydroepiandrosterone (DHEA).

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

SU10603, SU-10603, SU 10603

Compound Identifiers

PubChem CID

13083